18 and older, any sex, with Cervical Cancer or Anal Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Attitudes Toward HPV VaccinationPrimary· baseline posttest (test took approximately 5 minutes to complete)
Participants' attitudes toward HPV vaccination were measured by seven questions such as "The HPV vaccine is beneficial for adolescents." The responses were recorded on 1 (strongly disagree) to 5 (strongly agree) scales. Final score was the average of all 7 questions.
Group
Value
95% CI
Personalized Chatbot Condition
3.86
± .84
Non-Personalized Chatbot Condition
3.96
± .86
No Chatbot Control Condition
3.41
± .85
Intentions Toward HPV VaccinationPrimary· baseline posttest (test took approximately 5 minutes to complete)
Participants' intentions toward vaccinating their children against HPV were measured by three questions such as "I am likely to get my child/children the HPV vaccine." Responses were indicated on 1 (strongly disagree) to 5 (strongly agree) scales. The final score was the average of the three questions.
Group
Value
95% CI
Personalized Chatbot Condition
3.87
± 1.17
Non-Personalized Chatbot Condition
3.95
± 1.08
No Chatbot Control Condition
3.56
± 1.18
Ratings of the ChatbotSecondary· baseline posttest (test took approximately 5 minutes to complete)
Ratings of the Chatbot were measured by nine questions such as "How would you describe the HPV chatbot you just interacted with? - Engaging" on 1 (strongly disagree) to 5 (strongly agree) scales. The final score was the average of the nine questions.
Group
Value
95% CI
Personalized Chatbot Condition
4.10
± .79
Non-Personalized Chatbot Condition
4.16
± .70
Sponsor's own description
The goal of this project is to test the efficacy of a chatbot intervention for reducing HPV vaccine hesitancy among African American parents. An online experiment will be conducted to test the effectiveness of the chatbot intervention with African American parents. Results of this project will inform future communication interventions for reducing vaccine hesitancy among African American parents.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda
· Phase 2
· recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01
· Phase 1
· recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)
· NA
· recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India
· NA
· recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
· Phase 2
· recruiting
Other University of Maryland, College Park trials
Trials by the same sponsor.
NCT07134543 — Using the Smart Underwear Device to Determine a Baseline of Flatus Activity Normalized to Fiber Intake
· recruiting
NCT07162376 — How Clinical and Personal Information Shape Physicians' Risk Judgments
· NA
· completed
NCT06985641 — Khanya Ekhaya: A Home-Based Intervention
· NA
· not yet recruiting
NCT06724705 — Testing the Capability of the Smart Underwear Device to Detect Increased Microbiome Activity Following Lactose Consumpti
· NA
· recruiting
NCT06305039 — Optimizing Bilateral and Single-sided-deafness Cochlear Implants for Functioning in Complex Auditory Environments
· NA
· enrolling by invitation
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Maryland, College Park
Last refreshed: 21 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05959564.